tadalafil has been researched along with Cardiomyopathies, Primary in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Abuawad, Z; Andelova, K; Fulop, M; Kalocayova, B; Kura, B; Sagatova, A; Slezak, J; Sykora, M; Szeiffova Bacova, B | 1 |
| Guo, H; Hong, B; Jin, Z; Li, L; Zhang, J; Zhang, S; Zhi, H | 1 |
| Chau, VQ; Hoke, NN; Kukreja, RC; Salloum, FN | 1 |
| Ahmed, AA; Elnakish, MT; Floyd, K; Janssen, PM; Mohler, PJ; Saad, NS | 1 |
| Forbes, SC; Hammers, DW; Shima, A; Sleeper, MM; Sweeney, HL; Walter, GA | 1 |
| Das, A; Durrant, D; Koka, S; Kukreja, RC; Xi, L; Zhu, SG | 1 |
| Kukreja, RC | 1 |
7 other study(ies) available for tadalafil and Cardiomyopathies, Primary
| Article | Year |
|---|---|
The effect of selected drugs on the mitigation of myocardial injury caused by gamma radiation.
Topics: Animals; Atorvastatin; Cardiomyopathies; Free Radicals; Gamma Rays; Heart; Male; Malondialdehyde; Myocardium; Oxidative Stress; Radiation Injuries, Experimental; Rats; Tadalafil; Treatment Outcome; Tumor Necrosis Factor-alpha | 2021 |
Beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy.
Topics: Animals; Antibiotics, Antineoplastic; Atrophy; Carbolines; Cardiomyopathies; Cardiotonic Agents; Cyclic GMP; Disease Models, Animal; Doxorubicin; Fibrosis; Male; Mice; Mice, Inbred C57BL; Myocardium; Myocytes, Cardiac; Phosphodiesterase 5 Inhibitors; Signal Transduction; Tadalafil; Ventricular Dysfunction, Left | 2013 |
Tadalafil prevents acute heart failure with reduced ejection fraction in mice.
Topics: Animals; Apoptosis; Carbolines; Cardiomegaly; Cardiomyopathies; Coronary Vessels; Heart Failure; Male; Mice; Mice, Inbred ICR; Myocardial Infarction; Phosphodiesterase Inhibitors; Pulmonary Edema; Tadalafil; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2014 |
The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities.
Topics: Animals; Blood Pressure; Cardiomyopathies; Disease Models, Animal; Echocardiography; Electrocardiography; Heart Defects, Congenital; Heart Rate; Hemodynamics; Male; Mice; Myocardial Contraction; Niacinamide; Organ Size; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Tadalafil; Thyroxine | 2016 |
Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.
Topics: Animals; Cardiomyopathies; Cardiotonic Agents; Disease Models, Animal; Dogs; Dystrophin; Echocardiography; Humans; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred mdx; Muscular Dystrophy, Duchenne; Tadalafil; TRPC6 Cation Channel | 2016 |
Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Carbolines; Cardiomyopathies; Cell Line, Tumor; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Doxorubicin; GATA4 Transcription Factor; Genes, bcl-2; Hemodynamics; Lipid Peroxidation; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Myocytes, Cardiac; Neoplasm Transplantation; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Superoxide Dismutase; Tadalafil; Ultrasonography; Ventricular Function, Left | 2010 |
Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Antihypertensive Agents; Carbolines; Cardiomyopathies; Cardiovascular Agents; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Doxorubicin; Endothelium, Vascular; Enzyme Inhibitors; Erectile Dysfunction; Heart Failure; Humans; Hypertension; Hypertension, Pulmonary; Imidazoles; Male; Myocardial Infarction; Myocardial Reperfusion Injury; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents; Ventricular Remodeling | 2007 |